Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
about
Emerging utility of once-weekly exenatide in patients with type 2 diabetesRecommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profileThe short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United StatesExenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammationEffects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus PatientsCirculating glucagon-like peptide-1 increases in response to short-term overfeeding in men.Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programmeGlucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Composite endpoints in trials of type-2 diabetes.Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.GLP-1 Agonists and Blood Pressure: A Review of the Evidence.Exenatide: pharmacokinetics, clinical use, and future directions.Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
P2860
Q26777320-F39539A8-AD01-4352-94C4-51BD5661E7EBQ27687563-076EE179-A1C3-4884-8B47-9252DF025B06Q28545766-A813650D-F68F-4799-AA56-76C27E59BCD0Q33824522-E6189492-D874-49CD-96BA-6CD647EB14C7Q34405101-B5A7E8BC-ABA6-453C-950D-858A0E60CBAAQ36717057-C2214253-E394-43F9-9BC9-3CC5E309E0DDQ36766657-9C9D9591-E152-4E4A-A924-BDDFD64F8132Q37334002-D179AA85-512D-441E-A1C7-E368FC1BD403Q37402786-FBA411EE-6A36-464F-AE73-6CD19AFC18B7Q38154679-0E271B59-1B58-4803-AC34-8E63749BE520Q38430909-C8087427-5D15-43E2-B7DF-062CF9457E3DQ38709406-292F7423-37A6-4FEB-9D3E-FD90303442BCQ38770746-867E060B-99EE-432F-BB2C-A537287735C7Q47172049-6D8557EC-61A7-40F0-81A7-3F4A6F1D5E20
P2860
Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Exenatide once weekly improved ...... r hypoglycaemia, over 52 weeks
@ast
Exenatide once weekly improved ...... r hypoglycaemia, over 52 weeks
@en
type
label
Exenatide once weekly improved ...... r hypoglycaemia, over 52 weeks
@ast
Exenatide once weekly improved ...... r hypoglycaemia, over 52 weeks
@en
prefLabel
Exenatide once weekly improved ...... r hypoglycaemia, over 52 weeks
@ast
Exenatide once weekly improved ...... r hypoglycaemia, over 52 weeks
@en
P2093
P2860
P356
P1476
Exenatide once weekly improved ...... r hypoglycaemia, over 52 weeks
@en
P2093
P2860
P304
P356
10.1111/DOM.12026
P577
2012-11-12T00:00:00Z